Pfizer

News

Japan approves Pfizer COVID vaccine for children aged 5 to 1...

Japan's health ministry has authorised the use of Pfizer and BioNTech COVID-19 vaccine in children aged between five and 11.

News

GSK rejects $68.4bn Unilever bid for consumer health

GlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Healthcare in a deal worth approximately $68.4 billion (£

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Sarepta says early filing for DMD gene therapy may be back o...

The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the key players – Sarepta – thinks it may have the clinical data needed to file fo

News

scientifically visualization of a coronavirus spike protein

Pfizer, Moderna are prepping new vaccines for Omicron

With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of

R&D

Beyond the pandemic: the potential of mRNA technology

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of mo

Japan approves Pfizer COVID vaccine for children aged 5 to 1...

GSK rejects $68.4bn Unilever bid for consumer health

Sarepta says early filing for DMD gene therapy may be back o...

Pfizer, Moderna are prepping new vaccines for Omicron

Beyond the pandemic: the potential of mRNA technology

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks